Total Funding
4
21
Total FundingPost-IPO Debt raised
Growth Score
4 pts
Heat Score
-15 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
169873
Intercept Pharmaceuticals develops small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases.
Acquired by 
Interstellar Acquisition
Christian Weyer: Executive Vice President of Research & DevelopmentPast Role: Fate Therapeutics, President and Chief Executive Officer
Drew Cronin-Fine: Executive Director, US Marketing
About the Company
Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs
also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases
